Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 881-885

  Marques, Marisa B ^a   Brookings, Eneida S ^a   Moser, Stephen A ^a   Sonke, Phillip B ^b   Waites, Ken B ^a  

^a University of Alabama at Birmingham   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; GENTAMICIN; IMIPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN; TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; GENOTYPE; HOSPITAL INFECTION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030984308     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.881     Document Type: Article

References (35)

1. Allen, D. M., and B. J. Hartman. 1995. Acinetobacter species, p. 2009-2013. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y.
2. Anstey, N. M. 1992. Use of cefotaxime for treatment of Acinetobacter infections. Clin. Infect. Dis. 15:374.
3. Bergogne-Berezin, E., M. L. Joly-Guillou, and J. F. Vieu. 1987. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J. Hosp. Infect. 10:105-113.
4. Bouvet, P. J. M., and P. A. D. Grimont. 1986. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov. Acinetobacter haemolyticus sp. nov. Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and amended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int. J. Syst. Bacteriol. 35:228-240.
5. Bouvet, P. J. M., and P. A. D. Grimont. 1987. Identification and biotyping of clinical isolates of Acinetobacter. Ann. Ińst. Pasteur Microbiol. 138:569-578.
6. Bouvet, P. J. M., S. Jeanjean, J.-F. Vieu, and L. Dijkshoorn. 1990. Species, biotype, and bacteriophage type determinations compared with cell envelope protein profiles for typing Acinetobacter strains. J. Clin. Microbiol. 28:170-176.
7. Caillon, J., F. Guerif, L. Raskine, J. Jouanelle, and Y. Xiong. 1995. Comparative bactericidal activity of imipenem, piperacillin + tazobactam, ticarcillin + clavulanic acid alone and in combination with amikacin or sulbactam against Acinetobacter baumannii with different resistance phenotypes, abstr. E-101, p. 103. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Chang, S. C., Y. C. Chen, K. T. Luh, and W. C. Hsieh. 1995. In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Diagn. Microbiol. Infect. Dis. 23:105-110.
9. Chopade, B. A., P. J. Wise, and K. J. Towner. 1985. Plasmid transfer and behaviour in Acinetobacter calcoaceticus EBF65/65. J. Gen. Microbiol. 131: 2805-2811.
10. Crombach, W. H. J., L. Dijkshoorn, M. van Noort-Klaassen, J. Niessen, and G. van Knippenberg-Gordebeke. 1989. Control of an epidemic spread of a multidrug-resistant strain of Acinetobacter calcoaceticus in a hospital. Intensive Care Med. 85:624-631.
11. Devaud, M., F. H. Kayser, and B. Bachi. 1982. Transposon-mediated multiple antibiotic resistance in Acinetobacter strains. Antimicrob. Agents Chemother. 22:323-329.
12. Douboyas, J., L. S. Tzouvelekis, and A. Tsakris. 1994. In-vitro activity of ampicillin/sulbactam against multi drug-resistant Acinetobacter calcoaceticus var. anitratus clinical isolates. J. Antimicrob. Chemother. 34:298-300.
13. Drusano, G. L. 1991. Human pharmacodynamics of β-lactams, aminoglycosides and their combination. Scand. J. Infect. Dis. Suppl. 74:235-248.
14. Eliopoulos, G. M., and C. T. Eliopoulos. 1989. Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1:139-156.
15. Goldstein, F. W., A. Labigne-Roussel, G. Gerbaud, C. Carlier, E. Collatz, and P. Courvalin. 1983. Transferable plasmid-mediated antibiotic resistance in Acinetobacter. Plasmid 10:138-147.
16. Isenberg, H. D. 1992. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In Clinical microbiology procedures manual, vol. 1, p. 5.18.1-5.18.28. American Society for Microbiology, Washington, D.C.
17. Joly-Guillou, M. L., E. Bergogne-Berezin, and N. Moreau. 1987. Enzymatic resistance to β-lactams and aminoglycosides in Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 20:773-776.
18. Joly-Guillou, M. L., E. Bergogne-Berezin, and J. F. Vieu. 1990. A study of the relationships between antibiotic resistance phenotypes, phage-typing and biotyping of 117 clinical isolates of Acinetobacter sp. J. Hosp. Infect. 16:49-58.
19. Klastersky, J., F. Meunier-Carpentier, and J. M. Prevost. 1977. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am. J. Med. Sci. 273:157-167.
20. Marques, M. B., J. E. Mangino, B. B. Hines, S. A. Moser, and K. B. Waites. 1995. Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in a medical intensive care unit, abstr. L-33, p. 115. In Abstracts of the 95th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
21. Martinez-Martinez, L., G. Rodriguez, A. Pascual, A. I. Suarez, and E. J. Perea. 1995. In vitro activity of several antimicrobial combinations against multiresistant Acinetobacter baumannii, abstr. E-104, p. 104. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Meyers, B. R., P. Wilkinson, M. H. Mendelson, S. Walsh, C. Bournazos, and S. Z. Hirschman. 1991. Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob. Agents Chemother. 35:2098-2101.
23. National Committee for Clinical Laboratory Standards. 1994. Performance standards for antimicrobial susceptibility testing; fifth informational supplement. NCCLS document M100-S5, vol. 14. National Committee for Clinical Laboratory Standards, Villanova, Pa.
24. Physicians' Desk Reference. 1995. Physicians' desk reference, 49th ed. Medical Economics Data Production Co., Montvale, N.J.
25. Rogers, J. D., M. A. P. Meisinger, F. Ferber, G. B. Calandra, J. L. Demetriades, and J. A. Bland. 1985. Pharmacokinetics of imipenem and cilastatin in volunteers. Rev. Infect. Dis. 7(Suppl. 3):S435-S446.
26. Scully, B. E., N. Chin, and H. C. Neu. 1985. Pharmacology of ticarcillin combined with clavulanic acid in humans. Am. J. Med. 79:39-43.
27. Seifert, H., R. Baginski, A. Schulze, and G. Pulverer. 1993. Antimicrobial susceptibility of Acinetobacter species. Antimicrob. Agents Chemother. 37: 750-753.
28. Sorgel, F., and M. Kinzig. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. 31(Suppl. A):39-60.
29. Tilley, P. A., and F. J. Roberts. 1994. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin. Infect. Dis. 18:896-900.
30. Traub, W. H., and M. Spohr. 1989. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrob. Agents Chemother. 33:1617-1619.
31. Urban, C., E. Go, N. Mariano, B. J. Berger, I. Avraham, D. Rubin, and J. J. Rahal. 1993. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J. Infect. Dis. 167:448-451.
32. Urban, C., E. Go, N. Mariano, and J. J. Rahal. 1995. Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii. FEMS Microbiol. Lett. 125:193-198.
33. Vila, J., M. Almela, and M. T. Jimenez de Anta. 1989. Laboratory investigation of a hospital outbreak caused by two different multiresistant Acinetobacter calcoaceticus subsp. anitratus strains. J. Clin. Microbiol. 27:1086-1089.
34. Vila, J., A. Marcos, F. Marco, S. Abdalla, Y. Vergara, R. Reig, R. Gomez-Lus, and T. Jimenez de Anta. 1993. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 37:138-141.
35. Wang, G., T. S. Whittam, C. M. Berg, and D. E. Berg. 1993. RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing bacterial strains. Nucleic Acids Res. 21:5930-5933.